ESR1 and breast cancer: Sisci et al.55 reported that in breast cancer, FoxO3a overexpression decreased the motility, invasiveness, and anchorage-independent growth in estrogen receptor α-positive (ERα+) cells, while played an opposite role in ERα-silenced cells and in ERα-negative (ERα−) cell lines.